Additionally, investors should not forget that J.P. Morgan's exposure to macroeconomic cycles leaves it vulnerable to credit quality deterioration and reduced loan demand if economic growth falters.
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million.
J.P. Morgan Self-Directed Investing charges no commissions and offers a highly integrated app, which makes it a solid choice for individuals who want to trade their own investments — especially ...
Morgan Stanley stays bullish on Apple going into 2025, citing accelerated iPhone replacement cycles, double-digit services ... Among active stocks. J.P. Morgan upgraded Okta (OKTA) to Overweight ...
Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm SoftwareVANCOUVER, Wash., Jan. 08, ...